Abivax SA (FR:ABVX)
:ABVX
Want to see FR:ABVX full AI Analyst Report?
Top Page
Abivax SA
(ABVX)
Select Model
Select Model
Rating:46Neutral
Price Target:
€111.00
▲(6.02% Upside)
Action:Reiterated
Date:03/27/26
The score is primarily held back by weak financial fundamentals—large ongoing losses, zero 2025 revenue, and substantial cash burn—despite an improved 2025 balance sheet with low leverage. Technicals add pressure as the stock is below key moving averages with negative MACD, while valuation signals are limited because the company is loss-making and no dividend yield is provided.
Positive Factors
Balance sheet strength
An improved balance sheet with debt at about 7% of equity materially enhances funding flexibility for a clinical-stage biotech. Structurally, lower leverage reduces near-term refinancing risk and allows management to sustain multi-year R&D programs without immediate solvency pressure.
Negative Factors
Persistent cash burn
Consistent, large negative free cash flow means the company cannot self-fund development and must access external capital repeatedly. Over the medium term this raises dilution risk, can force timing changes to trials or programs, and makes execution contingent on capital markets and partners.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
An improved balance sheet with debt at about 7% of equity materially enhances funding flexibility for a clinical-stage biotech. Structurally, lower leverage reduces near-term refinancing risk and allows management to sustain multi-year R&D programs without immediate solvency pressure.
Read all positive factors
Abivax SA (ABVX) vs. iShares MSCI France ETF (EWQ)
Market Cap
€9.05B
Dividend YieldN/A
Average Volume (3M)99.97K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees69
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.83
Shares Outstanding79,694,534
10 Day Avg. Volume99,142
30 Day Avg. Volume99,970
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€125.00Price Target Upside19.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.24
Revenue Forecast (FY)€3.46M
Abivax SA Business Overview & Revenue Model
Company Description
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative ...
How the Company Makes Money
null...
Abivax SA Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 10.79M | 4.62M | 4.58M | 37.00K |
| Gross Profit | -1.07M | 10.79M | 4.49M | 4.51M | -119.00K |
| EBITDA | -249.55M | -167.68M | -133.21M | -53.31M | -42.20M |
| Net Income | -336.10M | -176.24M | -147.74M | -60.74M | -42.45M |
Balance Sheet | |||||
| Total Assets | 584.34M | 205.23M | 327.06M | 73.35M | 110.36M |
| Cash, Cash Equivalents and Short-Term Investments | 530.38M | 144.22M | 260.99M | 26.95M | 60.70M |
| Total Debt | 32.09M | 97.36M | 55.46M | 39.16M | 53.45M |
| Total Liabilities | 129.14M | 164.64M | 131.05M | 71.47M | 81.59M |
| Stockholders Equity | 455.20M | 40.58M | 196.01M | 7.19M | 25.93M |
Cash Flow | |||||
| Free Cash Flow | -162.23M | -154.72M | -97.39M | -69.55M | -47.30M |
| Operating Cash Flow | -162.09M | -154.07M | -97.13M | -65.58M | -45.66M |
| Investing Cash Flow | -13.72M | 15.76M | -8.10M | -3.73M | -1.46M |
| Financing Cash Flow | 553.80M | 28.21M | 335.29M | 32.21M | 82.68M |
Abivax SA Technical Analysis
Positive
104.70
Price Trends
102.24
Positive
102.13
Positive
94.09
Positive
Market Momentum
2.96
Negative
61.32
Neutral
78.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABVX, the sentiment is Positive. The current price of 104.7 is below the 20-day moving average (MA) of 105.75, above the 50-day MA of 102.24, and above the 200-day MA of 94.09, indicating a bullish trend. The MACD of 2.96 indicates Negative momentum. The RSI at 61.32 is Neutral, neither overbought nor oversold. The STOCH value of 78.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ABVX.
Abivax SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | €140.85M | -3.00 | -658.91% | ― | -77.92% | 11.11% | |
48 Neutral | €231.23M | -3.55 | -634.16% | ― | 291.43% | 12.24% | |
48 Neutral | €230.72M | -5.37 | -30.75% | ― | 32.62% | -7.59% | |
46 Neutral | €9.05B | -23.46 | ― | ― | ― | ― | |
42 Neutral | €954.31M | -10.01 | -241.12% | ― | ― | 27.51% | |
42 Neutral | €506.74M | -3.26 | -58.93% | ― | -15.98% | -54.34% |
* General Sector Average
FR:ABVX
Abivax SA
113.40
107.94
1976.92%
FR:IPH
Innate Pharma SA
1.61
-0.32
-16.74%
FR:DBV
DBV Technologies
3.36
1.98
143.13%
FR:TNG
Transgene
0.84
-0.15
-14.97%
FR:VLA
Valneva
2.61
-0.20
-7.11%
FR:ALCLS
Cellectis SA
3.08
1.72
126.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.